# 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

> **NCT04885855** · PHASE2,PHASE3 · COMPLETED · sponsor: **Muhammad Radzi Abu Hassan** · enrollment: 322 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Sofosbuvir 400 MG
- **DRUG:** Ravidasvir 200mg

## Key facts

- **NCT ID:** NCT04885855
- **Lead sponsor:** Muhammad Radzi Abu Hassan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-23
- **Primary completion:** 2023-12-29
- **Final completion:** 2024-03-15
- **Target enrollment:** 322 (ACTUAL)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04885855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04885855, "8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04885855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*